Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pelthos Therapeutics ( (PTHS) ) has issued an announcement.
On January 12, 2026, Pelthos Therapeutics and its subsidiaries entered into a senior secured venture loan and security agreement with Horizon Technology Finance for a term loan facility of up to $50 million, of which $30 million was funded at closing and an additional $20 million may be drawn upon achieving specified milestones. The facility, maturing in January 2031, carries interest at prime plus 3.75% with interest-only payments through at least early 2029, is secured by substantially all of the borrowers’ assets, and includes customary covenants and default provisions, while Pelthos also issued Horizon five-year warrants to purchase 65,488 common shares at $27.49 per share. According to the company’s January 13, 2026 announcement, the largely non‑dilutive financing is intended to accelerate commercialization of ZELSUVMI, support the launches of Xepi and Xeglyze, and bolster working capital, strengthening Pelthos’ balance sheet and providing growth capital for its expanding dermatology portfolio with limited equity dilution to existing shareholders.
The most recent analyst rating on (PTHS) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
Spark’s Take on PTHS Stock
According to Spark, TipRanks’ AI Analyst, PTHS is a Neutral.
The score is held back primarily by weak financial performance (large losses and substantial cash burn despite improving revenue), with valuation also constrained by negative earnings and no dividend support. These are partially offset by constructive earnings-call signals around the ZELSUVMI launch trajectory and a manageable leverage profile, while technicals remain broadly neutral.
To see Spark’s full report on PTHS stock, click here.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a biopharmaceutical company focused on commercializing innovative, safe and efficacious therapeutic products addressing unmet treatment needs, particularly in cutaneous infectious diseases. Its lead product, ZELSUVMI (berdazimer) topical gel 10.3% for molluscum contagiosum, received U.S. Food and Drug Administration approval in 2024, and the company is also advancing two recently acquired FDA-approved dermatology products, Xepi and Xeglyze. As of September 30, 2025, Pelthos held $14.2 million in cash, cash equivalents and investments, which was supplemented by a $18 million convertible notes issuance in November 2025.
Average Trading Volume: 24,672
Technical Sentiment Signal: Buy
Current Market Cap: $80.02M
For a thorough assessment of PTHS stock, go to TipRanks’ Stock Analysis page.